The funding round includes a grant from Innovate UK and strategic backing from Modality Partnership to develop hypertension and mental health services.
"Over 30% of hypertension patients are affected by anxiety or depression, impacting their ability to manage lifestyle behaviours consistently. At Holly Health, we have supported over 30,000 people so far and are committed to innovating to solve our biggest human and healthcare challenges. This funding marks a pivotal moment – with the support of Innovate UK and the strategic investment from Modality Partnership, we are empowered to combat the complex and unresolved challenge of multimorbidity."
The Series B round was co-led by Salesforce Ventures and Spark Capital to support product development for tendering teams.
"The investment in AutogenAI by Salesforce Ventures highlights our conviction that AutogenAI’s software is a game-changer for enterprises that secure business via tendering and drafting proposals,"
The largest European semiconductor venture funding round to date will support the construction of new fabrication lines in the UK.
"This successful Series D round is a clear testament to the massive opportunity for our innovative technology to enable item-level intelligence in virtually any object on the planet. Our global customers value our ultra-thin and flexible form factor, our breakthrough low cost of customisation and rapid production cycles, as well as the lower environmental footprint compared to silicon. Scaling our manufacturing capacity on the UK’s first ever 300mm wafer production lines at our site in Durham will enable us to deliver hundreds of billions of chips to customers worldwide over the coming decade."
